Windtree Therapeutics Inc (WINT)
4.49
+0.19
(+4.42%)
USD |
NASDAQ |
May 17, 16:00
4.41
-0.08
(-1.78%)
After-Hours: 20:00
Windtree Therapeutics Cash from Financing (TTM): 11.60M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 11.60M |
September 30, 2023 | 12.19M |
June 30, 2023 | 13.58M |
March 31, 2023 | 3.759M |
December 31, 2022 | 3.079M |
September 30, 2022 | 4.875M |
June 30, 2022 | 3.678M |
March 31, 2022 | 1.664M |
December 31, 2021 | 29.36M |
September 30, 2021 | 26.50M |
June 30, 2021 | 25.40M |
March 31, 2021 | 47.76M |
December 31, 2020 | 19.96M |
September 30, 2020 | 42.65M |
June 30, 2020 | 43.44M |
March 31, 2020 | 22.17M |
December 31, 2019 | 21.77M |
September 30, 2019 | 29.45M |
June 30, 2019 | 33.07M |
March 31, 2019 | 35.64M |
December 31, 2018 | 38.74M |
September 30, 2018 | 13.19M |
June 30, 2018 | 12.51M |
March 31, 2018 | 10.01M |
December 31, 2017 | 17.30M |
Date | Value |
---|---|
September 30, 2017 | 12.66M |
June 30, 2017 | 10.46M |
March 31, 2017 | 10.50M |
December 31, 2016 | 0.709M |
September 30, 2016 | 0.471M |
June 30, 2016 | 27.81M |
March 31, 2016 | 27.72M |
December 31, 2015 | 27.70M |
September 30, 2015 | 27.68M |
June 30, 2015 | -0.079M |
March 31, 2015 | -0.078M |
December 31, 2014 | 0.377M |
September 30, 2014 | 75.94M |
June 30, 2014 | 75.94M |
March 31, 2014 | 91.06M |
December 31, 2013 | 100.45M |
September 30, 2013 | 24.84M |
June 30, 2013 | 24.84M |
March 31, 2013 | 9.759M |
December 31, 2012 | 50.22M |
September 30, 2012 | 50.61M |
June 30, 2012 | 50.59M |
March 31, 2012 | 50.53M |
December 31, 2011 | 22.78M |
September 30, 2011 | 23.62M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
1.664M
Minimum
Mar 2022
47.76M
Maximum
Mar 2021
20.84M
Average
21.77M
Median
Dec 2019
Cash from Financing (TTM) Benchmarks
Lexicon Pharmaceuticals Inc | 428.17M |
AIM ImmunoTech Inc | 0.485M |
Perspective Therapeutics Inc | 167.19M |
Protalix BioTherapeutics Inc | 10.43M |
Armata Pharmaceuticals Inc | 59.32M |